Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
Vivace Therapeutics, a company that develops cancer treatments, announced on July 30, 2025, that the U.S. Food and Drug Administration (FDA) has granted its experimental
In this episode of MesoTV, Julie sits down with Meso Foundation board member and estate planning attorney, Cheryl Bruner. Cheryl is a member of the
Our Patient Services Director, Julie White, RN, BSN, OCN, sits down with Michael Offin, MD to discuss a clinical trial . Dr. Offin is a